Defective circulating CD4CD25 + Foxp3 + CD127 low regulatory t-cells in patients with chronic heart failure

Cellular Physiology and Biochemistry

Volumn 25, Issue 4-5, 2010, Pages 451-458

  Tang, Ting Ting ^a   Ding, Ying Jun ^a   Liao, Yu Hua ^a   Yu, Xian ^a   Xiao, Hong ^b   Xie, Jiang Jiao ^a   Yuan, Jing ^a   Zhou, Zi Hua ^a   Liao, Meng Yang ^a   Yao, Rui ^a   Cheng, Yan ^c   Cheng, Xiang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b NO1 Hospital of Wuhan   (China)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chronic heart failure; Immunity; Regulatory T cells

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CD4 ANTIGEN; CYTOKINE; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

EID: 77949931743     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000303050     Document Type: Article

References (32)

1. Brusko TM, Putnam AL, Bluestone JA: Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev 2008;223:371-390.
2. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA: CD127 expression inversely correlates with FOXP3 and suppressive function of human CD4+ Treg cells. J Exp Med 2006;203(7):1701-1711.
3. Crispin JC, Martinez A, Alcocer-Varela J: Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2003;21:273-276.
4. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, Ten S, Sanz M, Exley M, Wilson B, Porcelli S, Maclaren N: Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002;109:131-140.
5. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C: Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF alpha therapy. J Exp Med 2004;200(3):277-285.
6. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA: Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004;971:9-19.
7. Shen LS, Wang J, Shen DF, Yuan XL, Dong P, Li MX, Xue J, Zhang FM, Ge HL, Xu D: CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin Immunol 2009;131(1):109-118.
8. Hartl D, Koller B, Mehlhorn AT, Reinhardt D, Nicolai T, Schendel DJ, Griese M, Krauss-Etschmann S: Quantitative and functional impairment of pulmonary CD4+CD25hi regulatory T cells in pediatric asthma. J Allergy Clin Immunol 2007;119(5):1258-1266.
9. Torre-Amione G: Immune activation in chronic heart failure. Am J Cardiol 2005;95(11A):3C-8C.
10. Yndestad A, Holm AM, Müller F, Simonsen S, Frøland SS, Gullestad L, Aukrust P: Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res 2003;60(1):141-146.
11. Cheng X, Liao YH, Ge H, Li B, Zhang J, Yuan J, Wang M, Liu Y, Guo Z, Chen J, Zhang J, Zhang L: Th1/Th2 functional imbalance after acute myocardial infarction: coronary arterial inflammation or myocardial inflammation. J Clin Immunol 2005;25(3):246-253.
12. Athanassopoulos P, Vaessen LM, Maat AP, Balk AH, Weimar W, Bogers AJ: Peripheral blood dendritic cells in human end-stage heart failure and the early post-transplant period: evidence for systemic Th1 immune responses. Eur J Cardiothorac Surg 2004;25(4):619-626.
13. Lim HW, Hillsamer P, Kim CH: Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell-driven B cell responses. J Clin Invest 2004;114(11):1640-1649.
14. Mor A, Luboshits G, Planer D, Keren G, George J: Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J 2006;27(21):2530-2537.
15. Yndestad A, Damås JK, Oie E, Ueland T, Gullestad L, Aukrust P: Systemic inflammation in heart failure-the whys and wherefores. Heart Fail Rev 2006;11(1):83-92.
16. Adamopoulos S, Parissis JT, Kremastinos DT: A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail 2001;3(5):517-526.
17. Aukrust P, Ueland T, Lien E, Bendtzen K, Müller F, Andreassen AK, Nordøy I, Aass H, Espevik T, Simonsen S, Frøland SS, Gullestad L: Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999;83(3):376-382.
18. Omerovic E, Bollano E, Andersson B, Kujacic V, Schulze W, Hjalmarson A, Waagstein F, Fu M: Induction of cardiomyopathy in severe combined immunodeficiency mice by transfer of lymphocytes from patients with idiopathic dilated cardiomyopathy. Autoimmunity 2000;32(4):271-280.
19. Varda-Bloom N, Leor J, Ohad DG, Hasin Y, Amar M, Fixler R, Battler A, Eldar M, Hasin D: Cytotoxic T lymphocytes are activated following myocardial infarction and can recognize and kill healthy myocytes in vitro. J Mol Cell Cardiol 2000;32(12):2141-2149.
20. Maisel A, Cesario D, Baird S, Rehman J, Haghighi P, Carter S: Experimental autoimmune myocarditis produced by adoptive transfer of splenocytes after myocardial infarction. Circ Res 1998;82(4):458-463.
21. Bozkurt B, Kribbs SB, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL: Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998;97(14):1382- 1391.
22. Satoh S, Oyama J, Suematsu N, Kadokami T, Shimoyama N, Okutsu M, Inoue T, Sugano M, Makino N: Increased productivity of tumor necrosis factor-alpha in helper T cells in patients with systolic heart failure. Int J Cardiol 2006;111(3):405-412.
23. Fukunaga T, Soejima H, Irie A, Sugamura K, Oe Y, Tanaka T, Nagayoshi Y, Kaikita K, Sugiyama S, Yoshimura M, Nishimura Y, Ogawa H: Relation between CD4+ T-cell activation and severity of chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2007;100(3):483-488.
24. Izcue A, Coombes JL, Powrie F: Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev 2006;212:256-271.
25. Nie CQ, Bernard NJ, Schofield L, Hansen DS: CD4+ CD25+ regulatory T cells suppress CD4+ T-cell function and inhibit the development of Plasmodium berghei-specific TH1 responses involved in cerebral malaria pathogenesis. Infect Immun 2007;75(5):2275-2282.
26. DiPaolo RJ, Glass DD, Bijwaard KE, Shevach EM: CD4+CD25+ T cells prevent the development of organ-specific autoimmune disease by inhibiting the differentiation of autoreactive effector T cells. J Immunol 2005;175(11):7135- 7142.
27. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6(11):1123-1132.
28. Homey B. After TH1/TH2 now comes Treg/TH17: significance of T helper cells in immune response organization. Hautarzt. 2006;57(8): 730-732.
29. Cheng X, Yu X, Ding YJ, Fu QQ, Xie JJ, Tang TT, Yao R, Chen Y, Liao YH: The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol 2008;127(1):89-97.
30. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155(3):1151-1164.
31. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4(4):330-336
32. Mausner-Fainberg K, Luboshits G, Mor A, Maysel-Auslender S, Rubinstein A, Keren G, George J: The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 2008;197(2):829-839.